Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,267.00+0.58%ETH$2,510.86+2.27%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
QU

NASDAQ · QURE

uniQure N.V.

Healthcare · Biotechnology

$44.51

Up+$0.04 (+0.09%)

Updated Sep 13, 2026, 3:53 PM

SID Score

5.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.07B
P/E ratio
-4.92
Dividend yield
0.00%
52-week range
$13.21 – $51.72
Volume
1.24M
Avg. volume
4.73M

Price performance

QURE price history

1M range · 19 trading sessions · Daily adjusted prices

QURE closed at $44.51 after 19 trading sessions, down 7.21% for the selected period.

Last close
$44.51
Period change
-7.21%
Period low
$44.47
Period high
$51.05
Daily close
View OHLC price history
QURE OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 11, 2026$44.66$45.30$44.04$44.511.24M
Sep 10, 2026$45.68$45.82$44.40$44.47923.24K
Sep 9, 2026$45.71$46.98$45.37$46.001.35M
Sep 8, 2026$43.375$46.25$43.05$45.681.4M
Sep 4, 2026$44.91$45.16$43.90$44.50991.48K
Sep 3, 2026$45.50$46.03$44.03$44.861.32M
Sep 2, 2026$50.72$50.97$45.25$46.232.49M
Sep 1, 2026$48.63$48.8475$47.29$47.86748.86K
Aug 31, 2026$48.23$48.86$47.59$48.681.64M
Aug 28, 2026$49.51$49.51$48.29$48.72843.71K
Aug 27, 2026$50.83$51.03$49.51$49.56779.43K
Aug 26, 2026$50.90$51.195$50.05$50.95900.79K
Aug 25, 2026$48.00$51.7199$47.915$51.052.19M
Aug 24, 2026$48.00$48.036$46.34$47.46920.96K
Aug 21, 2026$48.91$49.845$48.19$48.37673.86K
Aug 20, 2026$48.00$49.64$47.08$48.891.2M
Aug 19, 2026$48.00$49.015$46.93$48.761.28M
Aug 18, 2026$47.42$48.20$46.8701$47.38501.34K
Aug 17, 2026$48.08$48.4999$46.87$47.97838.63K

Latest QURE news

The latest Smart Investors Daily articles mentioning QURE.

Stock researchCompany · Overview

QURE research

Overview

Company profile and research snapshot.

Company profile

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$55.67
Implied upside
—
Analysts
—
QURE recent ratings
DateFirmRatingTarget
Sep 2, 2026William BlairOutperform—
Jul 30, 2026Wells FargoOverweight—
Jul 30, 2026Wolfe ResearchOutperform—
Jul 30, 2026BarclaysOverweight—
Jun 29, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 4, 2026

ClearPoint Neuro (CLPT) Stock Sees Fair Value Cut As Analysts Factor In Heavier Investment

Price targets for ClearPoint Neuro have shifted toward the low to mid US$20s, with the average assessed fair value moving from US$28.33 to US$23.50 and one outlier still at US$30. Analysts link this change to a period they see as more investment heavy, balancing optimism about long term growth potential with caution around near term execution and partner related contributions. As you read on, you will see how this evolving narrative could shape the way you track ClearPoint Neuro from...

Yahoo · Sep 3, 2026

uniQure (QURE) Stock Could Be Fully Valued As It Files For AMT 130 Approval

After a very large three year gain in uniQure’s share price, the stock now screens as overvalued on market multiples and carries a mixed overall value score rather than a clear bargain signal. The recent run and the current valuation checks give investors a more finely balanced picture. Over the past three years, uniQure has returned very close to 7x for shareholders, which places extra focus on how much of the company’s future potential is already priced in. The recent Biologics License...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By